Navigation Links
Seahorse Launches Reagent to Make Functional Fatty Acid Oxidation (FAO) Assays Easy
Date:6/26/2012

BILLERICA, Mass., June 26, 2012 /PRNewswire/ -- Seahorse Bioscience, the world leader in manufacturing instrumentation and assay kits for measuring cellular metabolism, has announced the launch of its newest product, the XF Palmitate-BSA FAO Reagent, eliminating the need for radioactivity in fatty acid oxidation (FAO) assays.

The XF Palmitate-BSA FAO Reagent is a pre-conjugated, quality controlled fatty acid substrate in an aqueous solution that is readily absorbed and utilized by cells. Traditionally, FAO assays have been dependent on the Palmitate solubilizing, which is difficult to achieve and produces variable data.  

"For researchers probing substrate utilization and fatty acid oxidation pathways, the process is no longer dependent on one's ability to prepare Palmitate. Each lot of the Seahorse XF Palmitate-BSA Reagent is functionally tested for activity in a fatty acid oxidation assay on the XF Analyzer, ensuring consistent performance; and the pre-conjugated, non-radioactive, ready-to-use solution eliminates any requirement of a lengthy conjugation protocol, so the assay is no longer intimidating to the researcher", stated Steve Chomicz, Seahorse Vice President of Sales, Marketing & Support.

For use with both the XF96 and XF24 Extracellular Flux Analyzers, the new XF Palmitate-BSA FAO Reagent introduces a standardized, ready-to-use, quality-controlled solution for measuring fatty acid oxidation providing true functional information, and consistent results in every assay, without radioactivity.

The XF Palmitate-BSA FAO Reagent will further advance the study of cellular bioenergetics, helping scientists to better understand the connection of physiological traits of cells with genomic and proteomic data. This knowledge will generate new insights into cellular bioenergetics and mitochondrial dysfunction, leading to a greater understanding, and new treatments of diseases as the human lifespan increases.

About Seahorse Bioscience

Seahorse Bioscience provides instrumentation and kits for cellular bioenergetic analysis for biological research and drug discovery applications. Over 1,500 scientists worldwide are advancing their research in understanding the role of metabolism in Neurodegeneration, Aging, Cancer, Cardiovascular, Toxicology, Immunology, Obesity, Diabetes, Metabolic Disorders, and Translational Medicine. Founded in 2001, Seahorse Bioscience is headquartered in Billerica, Massachusetts, U.S., and has regional offices in Copenhagen, Denmark; and Shanghai, China.

CONTACT: Naomi Goumillout, +1-978-671-1619, ngoumillout@seahorsebio.com


'/>"/>
SOURCE Seahorse Bioscience, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. HemaClear Launches Activity in APAC
2. Elsevier Launches New Journal: Learning, Culture and Social Interaction
3. Bode Technology Launches Same-Day DNA Service For Faster Response to Law Enforcement and Justice System
4. ResearchMoz: Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar- Market Research Report
5. BioPharm Systems Launches Services to Help Phase I Clinics Implement Oracle Health Sciences LabPas
6. Pittcon 2013 Launches New Website
7. Comprehensive Resource for Food Safety Diagnostics – Romer Labs Launches New Website
8. Ekahau Launches Next Generation Wi-Fi RTLS Staff Badge and Pager
9. AMRI Launches SMARTSOURCING™ For Contract Manufacturing and Research Services
10. Neogen launches the fastest molecular pathogen test
11. Roche Launches 454 Sequencing Assays for High Sensitivity Genetic Variant Detection in Leukemia Samples to Drive Blood Cancer Research Worldwide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 01, 2016 , ... ... value of DNA microarray comparative genomic hybridization (array CGH) for HER2 genomic ... Symposium. Using molecular test results from tumors with previously documented positive, negative, ...
(Date:12/2/2016)... ... December 01, 2016 , ... PhUSE will build ... popularity of US Single Day Events (SDE) to organize a multiple-day US conference. ... Raleigh, NC. Topics of the pharmaceutical and life sciences industry will cover industry ...
(Date:12/2/2016)... ... December 01, 2016 , ... DrugDev believes the only ... a beautiful technology experience. All three tenets were on display at the 2nd Annual ... from over 40 sponsor, CRO and site organizations to discuss innovation and the future ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... consortium of pharmaceutical and biotechnology companies dedicated to collaboratively developing improved chemistry, ... in supplying a vendor-supported, portable online UHPLC, with robust, probe-based sampling. ...
Breaking Biology Technology:
(Date:11/22/2016)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is pleased to announce that the company has been ... Awards as "Most Outstanding in eClinical Solutions" for ... recognition and growth for MedNet, which has effectively supported ... iMedNet ™ , MedNet,s flagship eClinical technology ...
(Date:11/17/2016)... Global Market Watch: Primarily supported by ownership types; ... Academics) market is to witness a value of US$37.1 billion ... Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen from ... 2014-2020. North America is not way ... Europe at 9.56% respectively. Report Focus: ...
(Date:11/15/2016)... 2016  Synthetic Biologics, Inc. (NYSE MKT: SYN), ... the gut microbiome, today announced the pricing of ... its common stock and warrants to purchase 50,000,000 ... to the public of $1.00 per share and ... the offering, excluding the proceeds, if any from ...
Breaking Biology News(10 mins):